| Ryan Eldredge Wilcox, MD | |
|
1303 N Main St, Cedar City, UT 84721-9746 | |
| (435) 868-5690 | |
| Not Available |
| Full Name | Ryan Eldredge Wilcox |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 15 Years |
| Location | 1303 N Main St, Cedar City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033344767 | NPI | - | NPPES |
| P01103290 | Other | MN | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 7771656-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dixie Regional Medical Center | St george, UT | Hospital |
| Cedar City Hospital | Cedar city, UT | Hospital |
| Sevier Valley Hospital | Richfield, UT | Hospital |
| Garfield Memorial Hospital | Panguitch, UT | Hospital |
| Beaver Valley Hospital | Beaver, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
An unprecedented picture of how bacteria latch on to human cells has been published by UK, French and US scientists. They have produced a finely detailed model of one of the tools used by some of the nastiest varieties of the stomach bug, Escherichia coli, to stick to and gain entry to host cells.
Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Nationwide Children's Hospital has been selected as a Center of Excellence by the Batten Disease Support and Research Association (BDSRA), the largest research and support organization in North America for families that have children with Batten disease. BDSRA chose Nationwide Children's because of its clinical and research history with the disease and its ability to provide comprehensive care for these unique children.
› Verified 9 days ago
| Entity Name | Northeastern Utah Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982664199 PECOS PAC ID: 2961496609 Enrollment ID: O20040414000471 |
News Archive
An unprecedented picture of how bacteria latch on to human cells has been published by UK, French and US scientists. They have produced a finely detailed model of one of the tools used by some of the nastiest varieties of the stomach bug, Escherichia coli, to stick to and gain entry to host cells.
Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Nationwide Children's Hospital has been selected as a Center of Excellence by the Batten Disease Support and Research Association (BDSRA), the largest research and support organization in North America for families that have children with Batten disease. BDSRA chose Nationwide Children's because of its clinical and research history with the disease and its ability to provide comprehensive care for these unique children.
› Verified 9 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
An unprecedented picture of how bacteria latch on to human cells has been published by UK, French and US scientists. They have produced a finely detailed model of one of the tools used by some of the nastiest varieties of the stomach bug, Escherichia coli, to stick to and gain entry to host cells.
Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Nationwide Children's Hospital has been selected as a Center of Excellence by the Batten Disease Support and Research Association (BDSRA), the largest research and support organization in North America for families that have children with Batten disease. BDSRA chose Nationwide Children's because of its clinical and research history with the disease and its ability to provide comprehensive care for these unique children.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Eldredge Wilcox, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: () - | Ryan Eldredge Wilcox, MD 1303 N Main St, Cedar City, UT 84721-9746 Ph: (435) 868-5690 |
News Archive
An unprecedented picture of how bacteria latch on to human cells has been published by UK, French and US scientists. They have produced a finely detailed model of one of the tools used by some of the nastiest varieties of the stomach bug, Escherichia coli, to stick to and gain entry to host cells.
Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Nationwide Children's Hospital has been selected as a Center of Excellence by the Batten Disease Support and Research Association (BDSRA), the largest research and support organization in North America for families that have children with Batten disease. BDSRA chose Nationwide Children's because of its clinical and research history with the disease and its ability to provide comprehensive care for these unique children.
› Verified 9 days ago
Travis Petersen Jones, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1303 N Main St Ste 3c, Cedar City, UT 84721 Phone: 435-868-5500 | |
Dr. Philip E Smith, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1303 N Main St # 3c, Cedar City, UT 84720 Phone: 435-868-5500 | |
Todd Michael Garrett, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1303 N Main St, Cedar City, UT 84721 Phone: 435-868-5500 | |
Dr. Bruce Allen Hendrix, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1303 N Main St # 3c, Cedar City, UT 84720 Phone: 435-868-5500 | |
Karen Lin, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1303 N Main St, Cedar City, UT 84721 Phone: 435-868-5690 | |
Joseph Arnold Kaufman, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 105 N. Main St., Suite #206, Cedar City, UT 84720 Phone: 702-480-5253 Fax: 702-320-3849 |